N. Horscroft

发表

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

T. Schlake, A. Thess, M. Fotin‐Mleczek, 2017, EMBO molecular medicine.

Therapy with TLR7 Agonists Induces Lymphopenia: Correlating Pharmacology to Mechanism in a Mouse Model

Frances Burden, M. Fidock, C. Laxton, 2012, Journal of Clinical Immunology.

Neurotrophic Factor Expression After CNS Viral Injury Produces Enhanced Sensitivity to Psychostimulants: Potential Mechanism for Addiction Vulnerability

L. Parsons, G. Koob, T. Briese, 2000, The Journal of Neuroscience.

A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo

D. Gottardi, S. Possemiers, M. Martell, 2022, Biomedicines.

mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5

T. Schlake, L. Schöls, J. Gustafsson, 2019, Molecular therapy. Methods & clinical development.

Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV

M. Fidock, G. Ciaramella, T. Hickling, 2012 .

Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV

M. Fidock, G. Ciaramella, T. Hickling, 2012, Antiviral therapy.

Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice

J. Hennermann, S. Gehring, N. Horscroft, 2022, Frontiers in Bioengineering and Biotechnology.

Neuroprotection and Reduced Proliferation of Microglia in Ribavirin-Treated Bornavirus-Infected Rats

T. Briese, W. Lipkin, N. Horscroft, 2002, Antimicrobial Agents and Chemotherapy.

An infection-based model of neurodevelopmental damage.

W. Lipkin, M. Hornig, N. Horscroft, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Replicon Cell Culture System as a Valuable Tool in Antiviral Drug Discovery against Hepatitis C Virus

J. Wu, Z. Hong, W. Zhong, 2005, Antiviral chemistry & chemotherapy.

Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.

G. Song, A. Balakrishnan, Q. Yuan, 2021, Journal of hepatology.

NTP binding and phosphohydrolase activity associated with purified bluetongue virus non-structural protein NS2.

N. Horscroft, N J Horscroft, P Roy, 2000, The Journal of general virology.

Borna disease virus infection of adult and neonatal rats: models for neuropsychiatric disease.

W. Lipkin, M. Hornig, N. Horscroft, 2001, Current topics in microbiology and immunology.

Establishment of a Subgenomic Replicon for Bovine Viral Diarrhea Virus in Huh-7 Cells and Modulation of Interferon-Regulated Factor 3-Mediated Antiviral Response

Z. Hong, W. Zhong, R. Donis, 2005, Journal of Virology.

Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 Cells

Frances Burden, M. Westby, C. Smith-Burchnell, 2011, Antimicrobial Agents and Chemotherapy.

Antiviral applications of Toll-like receptor agonists.

D. Pryde, N. Horscroft, H. Bright, 2012, The Journal of antimicrobial chemotherapy.

Therapy with TLR7 Agonists Induces Lymphopenia: Correlating Pharmacology to Mechanism in a Mouse Model

Frances Burden, M. Fidock, C. Laxton, 2012, Journal of Clinical Immunology.

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

M. Fotin‐Mleczek, Brian C. Schanen, V. Wittman, 2017, Journal of Translational Medicine.

Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture.

I. W. Cheney, Z. Hong, W. Zhong, 2002, Virology.

Discovery of a highly potent series of TLR7 agonists.

G. Bish, D. Hay, James R. Hitchin, 2011, Bioorganic & medicinal chemistry letters.

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691)

M. Fidock, C. Laxton, M. Perros, 2011, Clinical pharmacology and therapeutics.

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

M. Fotin‐Mleczek, Brian C. Schanen, V. Wittman, 2017, Journal of Translational Medicine.

mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5

T. Schlake, L. Schöls, J. Gustafsson, 2019, Molecular therapy. Methods & clinical development.

Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].

G. Song, A. Balakrishnan, Q. Yuan, 2022, Journal of hepatology.

Investigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection

C. Laxton, T. Parkinson, N. Horscroft, 2007, Antimicrobial Agents and Chemotherapy.

Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies

M. Pönisch, N. Horscroft, Moritz Thran, 2023, Scientific reports.

Comparison of rat and human responses to toll-like receptor 7 activation.

Virgile Richard, C. Laxton, T. Parkinson, 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.